Abstract: Refractive outcomes at age two years of patients treated with intravitreal bevacizumab (IVB) or with conventional laser therapy (CLT) for zone 1 or zone 2 posterior stage 3+ ROP (who were enrolled in the BEAT-ROP clinical trial) will be presented.